ATE121946T1 - Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie. - Google Patents

Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.

Info

Publication number
ATE121946T1
ATE121946T1 AT90902952T AT90902952T ATE121946T1 AT E121946 T1 ATE121946 T1 AT E121946T1 AT 90902952 T AT90902952 T AT 90902952T AT 90902952 T AT90902952 T AT 90902952T AT E121946 T1 ATE121946 T1 AT E121946T1
Authority
AT
Austria
Prior art keywords
composition
preferably comprises
benich
treatment
methods
Prior art date
Application number
AT90902952T
Other languages
English (en)
Inventor
Muharrem Gokcen
Terry J Guy
Original Assignee
Immunolytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunolytics Inc filed Critical Immunolytics Inc
Application granted granted Critical
Publication of ATE121946T1 publication Critical patent/ATE121946T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT90902952T 1989-01-27 1990-01-19 Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie. ATE121946T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30380989A 1989-01-27 1989-01-27
US42996689A 1989-10-31 1989-10-31

Publications (1)

Publication Number Publication Date
ATE121946T1 true ATE121946T1 (de) 1995-05-15

Family

ID=26973659

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90902952T ATE121946T1 (de) 1989-01-27 1990-01-19 Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.

Country Status (10)

Country Link
US (1) US6296847B1 (de)
EP (1) EP0456724B1 (de)
JP (1) JP3054190B2 (de)
AT (1) ATE121946T1 (de)
AU (1) AU5045690A (de)
DE (1) DE69019141T2 (de)
DK (1) DK0456724T3 (de)
ES (1) ES2072424T3 (de)
HK (1) HK1003981A1 (de)
WO (1) WO1990008555A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4305460C2 (de) * 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
US7063838B1 (en) 1999-09-24 2006-06-20 Proteon Therapeutics Llc Methods for treating an artery or vein in a human subject
EP2332568A1 (de) * 1999-09-24 2011-06-15 Proteon Therapeutics, Inc. Kollagenase zur Öffnung verstopfter biologischer Kanäle
US6428785B1 (en) * 1999-10-28 2002-08-06 Immunolytics Inc. Method and composition for treating prostate cancer
US6678391B2 (en) * 2000-04-18 2004-01-13 Matsushita Electric Industrial Co., Ltd. Organism-specimen morphological-change detecting apparatus, and organism-specimen morphological-change detecting method
WO2002074329A1 (en) * 2001-03-19 2002-09-26 Ribeiro Santana Cristiano Albe Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process
WO2003066088A2 (de) * 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Protease-screening und neue verwendung von proteasen
EP1521523A4 (de) * 2002-05-20 2006-04-19 Univ Texas Verfahren und zusammensetzungen zur zuführung von enzymen und nukleinsäuremolekülen an gehirn, knochen und andere gewebe
US20060034824A1 (en) * 2002-09-19 2006-02-16 Santana Cristiano A R Pharmaceutical composition comprising carriers for products
US7437194B2 (en) * 2003-10-31 2008-10-14 Medtronic, Inc. Stimulating the prostate gland
MXPA03011987A (es) 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US7572613B2 (en) * 2004-06-25 2009-08-11 Klein Jeffrey A Drug delivery system for accelerated subcutaneous absorption
JP4913074B2 (ja) 2005-03-03 2012-04-11 アラーガン、インコーポレイテッド 動物由来産物不含方法およびボツリヌス毒素を精製するための方法
KR101447184B1 (ko) * 2006-11-10 2014-10-08 엘아이지에이디피 주식회사 게이트슬릿 개폐장치가 구비된 공정챔버
WO2008101098A2 (en) 2007-02-15 2008-08-21 Allergan, Inc. Use of botulinum toxin and enzymes for treating bladder or prostata disorders, or hyperhydrosis
AT506095A1 (de) * 2007-12-03 2009-06-15 Volopharm Gmbh Verwendung von proteasen
US8449512B2 (en) 2010-04-09 2013-05-28 Davinci Biomedical Research Products Inc. Stoma stabilitating device and method
WO2012109387A1 (en) * 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
MX350145B (es) * 2011-07-20 2017-08-28 Mediwound Ltd Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
CN111290143B (zh) 2012-08-10 2023-03-31 奥西奥公司以约利亚健康公司名义经营 隐形眼镜和为个体的眼睛测定隐形眼镜的适配的方法
US10835538B2 (en) * 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
US3792161A (en) 1970-05-18 1974-02-12 Research Corp Burn ointment comprising silver sulfadiazine and collagenase
US3678158A (en) 1971-05-11 1972-07-18 Worthington Bio Chem Corp Treatment of herniated intervertebral discs of mammals
US4276284A (en) 1971-07-26 1981-06-30 Brown Stuart I Prevention of collagenase induced disease by treatment with collagenase inhibitors
US3977408A (en) 1974-11-01 1976-08-31 Mackew Allan H Prosthetic catheter
US4005194A (en) 1975-06-23 1977-01-25 Abbott Laboratories Treatment of prostatic hyperplasia
US4317818A (en) 1976-05-10 1982-03-02 Richardson-Merrell Inc. Method of treating prostatic carcinoma
DE2655801C2 (de) 1976-12-09 1986-06-26 Kernforschungsanlage Jülich GmbH, 5170 Jülich Injizierbare Suspension von Membranvesikeln aus Erythrozyten und Verfahren zur Herstellung der Suspension
US4174389A (en) 1977-05-13 1979-11-13 Cope Louise A Ophthalmic use of collagenase
CH624011A5 (de) 1977-08-05 1981-07-15 Battelle Memorial Institute
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
US4329430A (en) * 1979-06-04 1982-05-11 Klein Gerold K V Enzyme mixture
US4317817A (en) 1979-08-27 1982-03-02 Richardson-Merrell Inc. Novel steroid 5α-reductase inhibitors
US4276281A (en) 1980-09-04 1981-06-30 Crikelair George F Burn treatment
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
JPS5826822A (ja) 1981-08-10 1983-02-17 Kaken Pharmaceut Co Ltd 慢性腎炎治療剤
JPS58189122A (ja) 1982-04-30 1983-11-04 Kaken Pharmaceut Co Ltd 高脂血症予防治療剤
JPS5951221A (ja) 1982-09-17 1984-03-24 Eisai Co Ltd 変形性関節症治療剤
IT1189379B (it) * 1982-10-08 1988-02-04 Serono Ist Farm Composizione farmaceutica contenente un agente fibrinolitico ed un fattore di diffusione,utile per il trattamento dell'infarto miocardico
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4659695A (en) * 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4678668A (en) * 1985-10-28 1987-07-07 Md Associates Method of reducing soft tissue swelling and pain
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy

Also Published As

Publication number Publication date
DE69019141D1 (de) 1995-06-08
JPH04503071A (ja) 1992-06-04
DE69019141T2 (de) 1996-01-18
EP0456724B1 (de) 1995-05-03
ES2072424T3 (es) 1995-07-16
HK1003981A1 (en) 1998-11-13
US6296847B1 (en) 2001-10-02
DK0456724T3 (da) 1995-10-02
WO1990008555A1 (en) 1990-08-09
JP3054190B2 (ja) 2000-06-19
EP0456724A1 (de) 1991-11-21
AU5045690A (en) 1990-08-24

Similar Documents

Publication Publication Date Title
ATE121946T1 (de) Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
AU2617901A (en) A method and composition for treating prostate cancer
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
TR199801151T2 (xx) Trombin inhibit�r� �n ila�lar.
EA200001044A3 (ru) Соединения для лечения женской сексуальной дисфункции
SE0001914D0 (sv) Förbättring av Peyronies sjukdom
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ATE249214T1 (de) Pentafluorobenzensulfonamide und analoge
DK1115701T3 (da) Arylsulfonanilidurinstoffer
ES2177112T3 (es) Agentes angiostaticos y composiciones para tratar el glaucoma glc1a.
EA200101089A1 (ru) Новый способ лечения
DE69935720D1 (de) Diamino-propanol-verbindungen zur behandlung von ischaemien
Lin et al. Degradation of type I collagen by rat mucosal keratinocytes. Evidence for secretion of a specific epithelial collagenase.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
DK180682A (da) Fremgangsmaade til fremstilling af et fibrinolytisk aktivt kar-princip og herved vundet enzymatisk produkt
IT1270993B (it) Derivati chinzolilamminici attivi come alfa-antagonisti
Polakoski et al. An acrosin-acrosin inhibitor complex in ejaculated boar sperm
AU9157901A (en) Methods of treating inflammatory and immune reactions and compositions therefor
KR890701099A (ko) 기침 및 기관지 협착을 치료하기 위한 5-ht3 수용기 길항물질
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
Singer et al. Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis
EP0817645A4 (de) Verfahren zur behandlung der gestartigen hypertrophie der prastate
DK1194109T3 (da) Topiske formuleringer omfattende hud-gennemtrængningsmidler samt anvendelse deraf
PT793666E (pt) Processo de sililacao

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee